Trump’s watered-down Medicare drug pricing rule saves 96% less than initial proposal
The Trump administration's finalized Medicare Part B drug pricing rule targets four companies, projected to save $440 million, a significant reduction from the initial proposal's estimated $12 billion in savings.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ The revised Medicare Part B drug pricing rule is projected to save $440 million.
- ✓ The initial proposal estimated $12 billion in savings.
- ✓ The revised policy represents a 96 percent reduction in expected cost savings.
What changed
The Trump administration finalized the revised Medicare Part B drug pricing rule, which is a watered-down version of the initial proposal.
Live updates
-
Trump's scaled-back Medicare drug pricing rule saves $440 million
The Trump administration's finalized Medicare Part B drug pricing rule targets four companies, projected to save $440 million, a significant reduction from the initial proposal's estimated $12 billion in savings.
Why it matters
The revised policy represents a 96 percent reduction in expected cost savings, according to Medicare actuaries. The initial proposal aimed to make Medicare Part B drug pricing more transparent and affordable. The scaled-back rule has been implemented amid criticism and controversy.
What is confirmed
- The revised Medicare Part B drug pricing rule is projected to save $440 million.
- The initial proposal estimated $12 billion in savings.
- The revised policy represents a 96 percent reduction in expected cost savings.
What to watch next
- Implementation details of the revised Medicare Part B drug pricing rule
- Reactions from the pharmaceutical industry and lawmakers
- Potential future adjustments to the rule
confidence 100%Sources used for this update (2)
- TribLIVE.com — News - TribLIVE.com
- www.intel.com — Intel Newsroom | News and Information
-
Trump administration reduces Medicare drug pricing savings by 96 percent
The Trump administration finalized a scaled-back GLOBE rule for Medicare Part B drug pricing that targets only four companies. This revised policy is projected to save $440 million, a sharp decline from the initial proposal's estimated $12 billion in savings. Medicare actuaries confirmed this adjustment represents a 96 percent reduction in expected cost savings.
Why it matters
The GLOBE rule intended to lower drug costs using a most-favored-nation pricing model. This shift suggests a significant retreat from the original goal of reducing government healthcare spending.
What is confirmed
- The finalized GLOBE rule targets only four companies.
- Expected cost savings for the revised policy are $440 million.
- The initial proposal for the GLOBE rule was projected to save nearly $12 billion.
- Medicare actuaries report a 96 percent reduction in expected savings compared to the initial proposal.
What to watch next
- Legal challenges to the finalized GLOBE rule
- Implementation dates for the new pricing model
- Official responses from the four targeted companies
confidence 100%Sources used for this update (2)
- www.fool.com — As AI Devours Memory Chips, the Companies That Make Them Hold the Pricing Power
- www.aarp.org — AARP Press Room | Media Releases & Corporate Updates
-
Trump Medicare Drug Rule Cuts Savings by 96 Percent
The Trump administration has finalized a significantly scaled-back version of the GLOBE rule designed to lower Medicare Part B drug prices through a most-favored-nation pricing model. While the initial proposal was projected to save nearly $12 billion, the revised policy now targets only four companies and drops expected cost savings down to $440 million. Medicare actuaries report that this adjustment represents a 96 percent reduction in expected savings from the initial proposal.
Why it matters
The administration previously advanced sweeping changes to lower prescription drug costs through international reference pricing. However, scaled-down regulatory implementations during the second term have substantially narrowed the economic impact of these health policies. Similar questions regarding transparency and limited scope have also surfaced around separate administration claims concerning Medicaid prescription drug savings.
What is confirmed
- The Trump administration finalized a scaled-back version of the GLOBE rule to lower Medicare Part B drug prices.
- The revised policy targets only four companies and drops expected cost savings down to $440 million.
- Medicare actuaries report the adjustment represents a 96 percent reduction in expected savings from the initial proposal of nearly $12 billion.
Still unconfirmed
- Deals struck with pharmaceutical companies are rescuing state budgets or helping to save Medicaid by saving tens of billions of dollars over a decade.
What to watch next
- Further regulatory adjustments or guidance tracking the implementation of the GLOBE rule
- Additional disclosures clarifying the exact scope and drug coverage of pharmaceutical pricing deals
confidence 100%Sources used for this update (9)
- www.brookings.edu — Tracking regulatory changes in the second Trump administration
- www.aljazeera.com — United States | United States | Today's latest from Al Jazeera
- www.nyc.gov — News - NYC Mayor's Office
- TribLIVE.com — Western PA Local News
- en.wikipedia.org — Tariffs in the second Trump administration - Wikipedia
- www.factcheck.org — Trump Touts Medicaid Drug Savings, But Details Remain Murky
- www.pcubed.jp — トランプ政権のメディケア医薬品価格規制により、当初案に比べ節約効...
- www.kfvs12.com — KFVS12 | Heartland News, Weather, and Sports | Cape Girardeau, MO
- en.wikipedia.org — List of people granted executive clemency in the second Trump ...
-
Trump Finalizes Weakened Medicare Part B Drug Pricing Rule
The Trump administration has finalized a significantly scaled-back version of its GLOBE rule, lowering Medicare Part B drug prices through a most-favored nation pricing model. Originally projected to save nearly $12 billion, the revised policy now targets only four companies and drops expected cost savings down to $440 million. Medicare actuaries report this adjustment represents a 96 percent reduction in expected savings from the initial proposal.
Why it matters
Drug pricing policy remains a central focus for the White House as political attention shifts toward upcoming midterm elections. The administration originally proposed a broad pricing model designed to tackle high pharmaceutical costs. The sharp reduction in projected savings reflects the narrow scope of the final regulation.
What is confirmed
- The Trump administration finalized the GLOBE rule to lower Medicare Part B drug prices using a most-favored nation pricing model.
- The final rule applies to only four companies.
- Medicare actuaries estimate projected savings dropped from nearly $12 billion in the original proposal to $440 million.
- The change represents a 96 percent reduction in expected cost savings.
- Donald J. Trump serves as the 47th president of the United States after returning to the White House following the 2024 election.
What to watch next
- Implementation details and timelines for the four affected companies under the finalized GLOBE rule.
- Further administration announcements regarding pharmaceutical pricing ahead of the midterm elections.
confidence 100%Sources used for this update (5)
- www.theguardian.com — Donald Trump - The Guardian
- en.wikipedia.org — Donald Trump - Wikipedia
- www.whitehouse.gov — President Donald J. Trump - The White House
- www.whitehouse.gov — Trump TV – The White House
- time.com — Fact-Checking What Donald Trump Said in His 2026 Interview ...
-
Trump Administration Finalizes Medicare Drug Pricing Rule With Reduced Savings
The Trump administration finalized the GLOBE rule to lower Medicare Part B drug prices using a most-favored nation pricing model. The final rule is significantly more limited than the initial proposal, applying to only four companies. Medicare actuaries estimate the projected savings dropped from nearly $12 billion in the original proposal to $440 million, representing a 96% reduction in expected cost savings.
Why it matters
The rule aims to align US Medicare payments for certain drugs with lower prices paid in other developed nations. This effort targets high-cost prescriptions within the Part B program. The sharp decline in projected savings indicates a substantial narrowing of the policy's scope.
What is confirmed
- The Trump administration finalized a Medicare drug pricing rule known as the GLOBE rule.
- The final rule applies to only four companies.
- Medicare actuaries estimate projected savings fell from nearly $12 billion in the proposed rule to $440 million.
- The finalized rule delivers 96% less savings than the initial proposal.
- The model aims to bring most-favored nation pricing to Medicare Part B.
What to watch next
- Legal challenges from the four affected pharmaceutical companies
- Implementation timelines for the most-favored nation pricing model
confidence 100%Sources used for this update (9)
- WSJ — Trump Administration Finalizes Plan to Lower Drug Prices in Medicare
- STAT — Trump’s watered-down Medicare drug pricing rule saves 96% less than initial proposal
- Yahoo — What Medicaid’s New Payment Model Means For Your Prescriptions
- Fierce Healthcare — CMS finalizes model that aims to bring most-favored nation pricing to Part B
- Endpoints News — CMS finalizes GLOBE rule as projected Medicare savings fall from $11.9B to $440M
- www.statnews.com — Trump’s watered down drug pricing rule saves 96% less than ...
- catalystalert.io — Trump’s watered down drug pricing rule saves 96% less than ...
- www.statnews.com — Pharmalittle: Medicare drug-price rule saves far less than ...
- www.worldpingnews.com — Swiss glaciers suffer 'disastrous' year of ice loss ...
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community